Rimegepant (Vydura®). HTA ID: 22051

Assessment Status Full HTA submission received from Applicant
HTA ID 22051
Drug Rimegepant
Brand Vydura®
Indication For the acute treatment of migraine with or without aura in adults; and for the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month.
Assessment Process
Rapid review commissioned 13/07/2022
Rapid review completed 12/09/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of rimegepant (Vydura®) compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 28/09/2022
Pre-submission consultation with Applicant 10/11/2022
Full submission received from Applicant 07/02/2023